Therapeutic significance of a D-dimer cut-off level of >3 μg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab

Japanese Journal of Clinical Oncology

Volumn 40, Issue 10, 2010, Pages 933-937

  Mochizuki, Satoshi ^a   Yoshino, Takayuki ^a   Kojima, Takashi ^a   Fuse, Nozomu ^a   Ikematsu, Hiroaki ^a   Minashi, Keiko ^a   Yano, Tomonori ^a   Tahara, Makoto ^a   Kaneko, Kazuhiro ^a   Doi, Toshihiko ^a   Koike, Kazuhiko ^b   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bevacizumab; Colorectal neoplasms; Fibrin fragment D; ROC curve; Venous thromboembolism

Indexed keywords

BEVACIZUMAB; D DIMER; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVARY METASTASIS; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEPSIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEPSIS; VENOUS THROMBOEMBOLISM;

EID: 77957700685     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq058     Document Type: Article

References (13)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5: 632-4.
2. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E32J Clin Oncol 2007;25:1539-44.
5. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
6. Brown MD, Lau J, Nelson RD, Kline JA. Turbidimetric D-dimer test in the diagnosis of pulmonary embolism: a metaanalysis. Clin Chem 2003;49:1846-53.
7. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-35.
8. Edwards CM, Warren J, Armstrong L, Donnelly PK. D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Surg 1993;80:1404-5.
9. van Duijnhoven EM, Lustermans FA, van Wersch JW. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis 1993;23:168-72.
10. Yoshikawa R, Yanagi H, Noda M, Ikeuchi H, Nakano H, Gega M, et al. Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. Oncol Rep 2005;13:627-32.
11. Francis CW, Felcher AH, White J, Braaten JV, Goss R. Thrombin activity associated with indwelling central venous catheters. Thromb Haemost 1997;77:48-52.
12. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101:77-82.
13. Mochizuki S, Yoshino T, Fukushima T, Fuse N, Ikematsu H, Minashi K, et al. Therapeutic significance of D-dimer cut-off level of more than 3μg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. 2009 Gastrointestinal Cancers Symposium 2009; Abstract No. 312.